Invo Bioscience, Inc. INVO
Institutional shares held
14,062
0
calls
0
puts
Total value of holdings
$9K
$0
calls
$0
puts
Market Cap
$8.52M
12,169,700
Shares Out.
Institutional ownership
0.12%
# of Institutions
1
We take great care to ensure that the data presented and summarized in this overview for INVO Bioscience, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INVO
View allLatest Institutional Activity in INVO
Top Purchases
Top Sells
About INVO
INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.
Insider Transactions at INVO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 01
2022
|
Kevin Doody Medical Director |
SELL
Open market or private purchase
|
Direct |
177,306
-100.0%
|
$0
$0.95 P/Share
|
|
Jun 01
2022
|
Rebecca Messina Director |
BUY
Open market or private purchase
|
Direct |
9,868
+29.98%
|
$0
$0.95 P/Share
|
|
Jun 01
2022
|
Andrea Goren Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
52,632
+28.97%
|
$0
$0.95 P/Share
|
|
Jun 01
2022
|
Michael Jos. Campbell Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
10,526
+12.2%
|
$0
$0.95 P/Share
|
|
Jun 01
2022
|
Jeffrey Segal Director |
BUY
Open market or private purchase
|
Direct |
9,211
+24.61%
|
$0
$0.95 P/Share
|
|
Jun 01
2022
|
Trent D Davis Director |
BUY
Open market or private purchase
|
Direct |
11,184
+24.96%
|
$0
$0.95 P/Share
|
|
Jun 01
2022
|
Barbara Ryan Director |
BUY
Open market or private purchase
|
Direct |
10,526
+31.41%
|
$0
$0.95 P/Share
|
|
Jun 01
2022
|
Matthew K Szot Director |
BUY
Open market or private purchase
|
Direct |
14,474
+26.98%
|
$0
$0.95 P/Share
|
|
Jun 01
2022
|
Steve Shum Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
58,885
+31.44%
|
$0
$0.95 P/Share
|
|
Jan 15
2022
|
Andrea Goren Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,361
+23.09%
|
-
|
|
Jan 15
2022
|
Barbara Ryan Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,588
+28.97%
|
-
|
|
Jan 15
2022
|
Rebecca Messina Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,311
+38.68%
|
-
|
|
Jan 15
2022
|
Matthew K Szot Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,250
+29.33%
|
-
|
|
Jan 15
2022
|
Steve Shum Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,111
+19.69%
|
-
|
|
Jan 15
2022
|
Michael Jos. Campbell Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,236
+18.93%
|
-
|
|
Jan 15
2022
|
Jeffrey Segal Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,034
+30.85%
|
-
|
|
Jan 15
2022
|
Kevin Doody Medical Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,480
+4.05%
|
-
|
|
Jan 15
2022
|
Trent D Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,865
+28.32%
|
-
|
|
Oct 05
2021
|
Steve Shum Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
30,674
+33.13%
|
$92,022
$3.26 P/Share
|
|
Oct 05
2021
|
Andrea Goren Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
30,674
+28.65%
|
$92,022
$3.26 P/Share
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders